Intelligence · Clinical pipeline
Oncology · Phase II
Oncology programs at Phase II — ClinicalTrials.gov pipeline intelligence.
Quick answer
Oncology Phase II programs: NovaPharmaNews indexes 2,637 matching clinical development programs from ClinicalTrials.gov with sponsor, modality, and NCT cross-links.
Top sponsors
- First People's Hospital 261 programs
- Chinese Academy of 198 programs
- George Institute for 118 programs
- United Therapeutics Europe 112 programs
- Telethon Foundation 91 programs
- Takeda 79 programs
- Regeneron UK 71 programs
- MSD Merck Sharp 63 programs
- Ningbo Cancer Hospital 62 programs
- Anaxis Pharma 57 programs
- AstraZeneca 52 programs
- HOFFMANN-LA ROCHE 50 programs
Pipeline programs
-
Clostridium Butyricum Tablets
The First People's Hospital of Lianyungang
Bladder (Urothelial, Transitional Cell) Cancer
1 trial -
Cobimetinib
Hoffmann-La Roche
Solid Tumors
1 trial -
Colonoscopy with enhanced dye
Cardiff Oncology
Colorectal Cancer
1 trial -
Combination of MK3475 with Metronomic CP
Lxo Ireland Designated Activity Company
Sarcoma
1 trial -
Combination of Palbociclib and aromatase inhibitor (Letrozole or Anastrozole)
United Therapeutics Europe Ltd
Hormonal Receptors Positive, HER2 Negative, Advanced Breast Cancer
1 trial -
Combination therapy (COMB)
The First People's Hospital of Lianyungang
Esophageal Squamous Cell Carcinoma (ESCC)
1 trial -
Combinations
The First People's Hospital of Lianyungang
Colorectal Cancer
1 trial -
Conventional Roux-en-Y Gastrojejunostomy
The First People's Hospital of Lianyungang
Gastric Cancer
1 trial -
Coriolus Versicolor
Hospital Authority, Hong Kong
Carcinoma
1 trial -
Cotellic 20 mg film-coated tablets, Ginisortamab
Ningbo Cancer Hospital
Metastatic pancreatic ductal adenocarcinoma
1 trial -
Cretostimogene Grenadenorepvec
CG Oncology
High-Risk Non-Muscle-Invasive Bladder Cancer
1 trial -
Cyclophosphamide
Takeda
B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
1 trial -
Cyclophosphamide
Iovance Biotherapeutics B.V.
Clinical Stage IV Cutaneous Melanoma AJCC v8
1 trial -
Cyclophosphamide
Iovance Biotherapeutics B.V.
Metastatic Bladder Urothelial Carcinoma
1 trial -
Cyclophosphamide
The First People's Hospital of Lianyungang
Acute Lymphoblastic Leukemia, Pediatric
1 trial -
Cyclophosphamide
United Therapeutics Europe Ltd
Metastatic Melanoma
1 trial -
Cyclophosphamide
BEONE MEDICINES AUS PTY LTD
Recurrent Transformed Chronic Lymphocytic Leukemia
1 trial -
Cyclophosphamide
ADC Therapeutics SA
Double-Expressor Lymphoma
1 trial -
Cyclophosphamide Doxorubicin Vincristine Lamivudine
Taiwan Liposome Company
Non-Hodgkin's Lymphoma
1 trial -
Cyclophosphamide+Pemetrexed+5-Fluorouracil
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Locally Advanced Thyroid Gland Carcinoma
1 trial -
Cyproterone acetate 5
Teva Pharma GmbH
Prostate Cancer
1 trial -
Cyramza /ml concentrate for stomach cancer stage IV with me…
CERO THERAPEUTICS HOLDINGS, INC.
stomach cancer stage IV with metastases
1 trial -
Cytarabine
Teva Pharma GmbH
Acute Myeloid Leukemia
1 trial -
Cytarabine
Jazz Pharmaceuticals Ireland Limited
Leukemia
1 trial -
Cytarabine
Kura Oncology
Acute Myeloid Leukemia
1 trial -
Cytarabine and Idarubicin
Jazz Pharmaceuticals Ireland Limited
Acute Myeloid Leukemia
1 trial -
Cytokine-induced killer cells
The First People's Hospital of Lianyungang
Ovarian Carcinoma
1 trial -
Cytokine-induced killer cells
The First People's Hospital of Lianyungang
Melanoma
1 trial -
D20181321
Pari Pharma GmbH
recurrent primary supratentorial malignant brain tumors in children
1 trial -
D361FC00001
AstraZeneca AB
Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
1 trial -
D4190C00022
AstraZeneca AB
Hepatocellular Carcinoma
1 trial -
D419EC00001
AstraZeneca AB
Advanced Solid Tumors
1 trial -
D5162C00048
AstraZeneca AB
Non-Small Cell Lung Cancer
1 trial -
D516AC00003
AstraZeneca AB
Unresectable Non-small Cell Lung Cancer
1 trial -
D5336C00001
AstraZeneca AB
Triple Negative Breast Cancer
1 trial -
D533AC00001
AstraZeneca AB
Unresectable or Advanced Melanoma
1 trial -
D6132C00001
AstraZeneca AB
First-line patients with extensive disease small-cell lung cancer (SCLC)
1 trial -
D6186C00001
AstraZeneca AB
Advanced Non-Small Cell Lung Cancer
1 trial -
D6187C00001
AstraZeneca AB
Non-Small Cell Lung Cancer
1 trial -
D702KC00001
AstraZeneca AB
metastatic non-small cell lung cancer (NSCLC)
1 trial -
D7080C00001
AstraZeneca AB
Non Small Cell Lung Cancer Colorectal Cancer Pancreatic Ductal Adenocarcinoma
1 trial -
D7407C00001
AstraZeneca AB
Mantle Cell Lymphoma, Large B-Cell Lymphoma, Chronic Lymphocytic Leukaemia, Small Lymphocytic Lymphoma
1 trial -
D7986C00001
AstraZeneca AB
Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
1 trial -
D798KC00001
AstraZeneca AB
Solid Tumors, SQ, NSQ NSCLC
1 trial -
D798MC00002
AstraZeneca AB
Sub-study 5: Unresectable Pleural Mesothelioma (Volrustomig Monotherapy), Sub-study 4: Esophageal Squamous Cell Carcinoma (Volrustomig in Combination with Chemotherapy).
1 trial -
D8220C00036
AstraZeneca AB
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
1 trial -
D822GC00001
AstraZeneca AB
Treatment Naïve Mantle Cell Lymphoma
1 trial -
D8410C00001
AstraZeneca AB
Module 1: advanced/relapsed ovarian, breast, pancreatic or prostate cancer where patients loss of function or predicted loss of function mutation in BRCA1, BRCA2, PALB2, RAD51C, or RAD51D, Module 4: advanced,unresectable and HER2+ metastatic solid tumours; NSCLC, HER2 activating mutation, Module 5: advanced,unresectable or metastatic solid tumours in breast, endometrial, ovarian and prostate cancer, Module 3: advanced/relapsed HER2-negative breast, ovarian, prostate, or pancreatic cancer and expressing BRCA1m, BRCA2m, PALB2m, RAD51Cm or RAD51Dm, IDH-mutant recurrent glioma, breast cancer (without BM), Module 2: IDH-mutant glioma
1 trial
Frequently asked questions
How many oncology Phase II programs exist?
2,637 programs match both the therapeutic area and stage filters in our published index.